Bing

SEARCH HISTORY

Roche will publish its Half Year Results for 2015 prior to the opening of the Swiss Stock Exchange on 23rd July ... 07/15 ROCHE BEARER SHARE: Genentech Reports Findings of the IMvigor 210 study 07/14 ROCHE …
4 Traders · 7/16/2015
Genentech/ Roche Holding AG [RHHBY:OTCQX]; allowed at the discretion of the treating investigator), it achieved liver-only PFS for a median 20.5 months. That was a near eight-month extension in PFS, which was …
Commodity Online · 7/23/2015
SAN FRANCISCO and HAMBURG, Germany, July 24, 2015 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt Stock Exchange:EVT ... Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition …
Financial Content · 7/24/2015
Gladstone Institutes
Update | 5:51 p.m. Shares of Genentech climbed on Monday afternoon following reports that the biotechnology company was close to a deal to be acquired by Roche Holding for $95 a share. Genentech’s shares rose for a time above Roche’s most …
Deal Book · 3/9/2009
Fourth-quarter profits at high-flying Genentech soared 64 percent, but analysts were chilled by the news that revenue from its best-selling Avastin hadn't reached their lofty projections. Genentech's stock dropped 3 percent, despite Avastin's $359 million ...
Fierce Biotech · 1/10/2006
NEW YORK (CNNMoney.com) - Genentech's stock jumped more than 5 percent on Friday after the biotech said its earnings would surge by up to 50 percent in 2006. The biotech, based in South San Francisco, also said it expects to bring 15 new products …
CNN Money · ByAaron Smith · 3/17/2006
The board maintained the maximum number of shares that can be repurchased at 100 million shares, the biotechnology company said in a statement. (Reporting by Neetha Mahadevan in Bangalore)
Reuters · 4/20/2007
The approval sent the Genentech stock to its highest point since October 2000, closing at $103.10, up 7.3%. But for rival ImClone Systems, which has also just won approval for colon cancer drug Erbitux, the news sent shares down 1.5% to close at $42.80.
usatoday30.usatoday.com · ByLiz Szabo andJulie Appleby · 2/26/2004
Genentech Inc.'s stock slipped 5.3% on Tuesday as investors winced at news that the U.S. attorney's office in Philadelphia was conducting an investigation into the marketing of the firm's top-selling drug, Rituxan. Shares in the world's second-largest ...
Los Angeles Times · 10/6/2004
This is typically done for medicines that need special handling, such as refrigeration, or expensive pharmaceuticals, which customers do not typically hold in stock. She declined to discuss terms of its arrangement with Genentech. The Genentech
The Wall Street Journal · 10/4/2014